FibroGen, Inc. FGEN
Jan 12, 2026, 9:30 AM EST
52-week range unavailable
- YTD
- +3.30%
- 1 year
- -41.90%
- Market cap
- 48.37M
- Revenue (ttm)
- 173.82M
- Profit margin
- -96.84%
- Shares out
- 100.77M
- Forward P/E
- -0.70
- YTD return
- +3.30%
- 1-year return
- -41.90%
- Volume
- 29.25K
- Open
- 9.10
- Previous close
- 9.07
- Day's range
- 9.02 – 9.21
- Beta
- 0.73
- Analysts
- Hold
- Price target
- 10.00 (+10.3%)
2Y -13.05 (-57.87%)
Key statistics
- Enterprise value
- 103.85M
- PEG ratio
- 0.00
- Price / sales
- 0.28
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 14.30%
- Free cash flow
- -121.83M
- Total cash
- 140.71M
- Total debt
- 163.78M
- Return on equity
- 0.00%
- Short % of float
- 5.07%
- 50-day average
- 0.35386
- 200-day average
- 0.852785
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.20.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.38 | -0.17 | +0.21 | +55.26% |
| Aug 6, 2024 | Jun 1, 2024 | -0.26 | -0.16 | +0.10 | +38.46% |
| May 6, 2024 | Mar 1, 2024 | -0.31 | -0.33 | -0.02 | -6.45% |
| Feb 26, 2024 | Dec 1, 2023 | -0.42 | -0.57 | -0.15 | -35.71% |
| Nov 6, 2023 | Sep 1, 2023 | -0.68 | -0.52 | +0.16 | +23.53% |
| Aug 7, 2023 | Jun 1, 2023 | -0.72 | -0.65 | +0.07 | +9.72% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 8, 2023 | B of A Securities | down | Neutral | Underperform |
| Jun 27, 2023 | Goldman Sachs | main | Sell | Sell |
| Jun 27, 2023 | Raymond James | down | Outperform | Market Perform |
| Jun 26, 2023 | B of A Securities | down | Buy | Neutral |
| Jun 26, 2023 | Stifel | down | Buy | Hold |
| Jun 26, 2023 | Raymond James | down | Outperform | Market Perform |
About FibroGen, Inc.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- fibrogen.com
News
Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results 
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 
FibroGen (NASDAQ:FGEN) Stock Crosses Above Fifty Day Moving Average – Here’s Why 
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum 
12 Health Care Stocks Moving In Monday's After-Market Session 
FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript 
FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates 
FibroGen to Report Third Quarter 2025 Financial Results 
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer 
FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Your note
Sign in to keep a note on FGEN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADIB DEYAA | Officer | Purchase | Jun 11, 2024 | 82,123 |
| BLAUG SUZANNE | Director | Sale | Jun 8, 2023 | 29,594 |
| BRENNAN AOIFE M | Director | Sale | Jun 8, 2023 | 27,947 |
| CHUNG CHRISTINE | Officer | Stock Award(Grant) | Mar 5, 2024 | 341,028 |
| CONTERNO ENRIQUE A | Chief Executive Officer | Sale | Jul 6, 2023 | 402,522 |
| CRAVATT BENJAMIN PH.D. | Director | Sale | Jun 8, 2023 | 28,736 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Primecap Management Company | 9.84% | 9,911,231 | 4.76M | Sep 29, 2024 |
| Armistice Capital, LLC | 6.75% | 6,800,000 | 3.26M | Sep 29, 2024 |
| Vanguard Group Inc | 5.84% | 5,882,361 | 2.82M | Sep 29, 2024 |
| Acadian Asset Management. LLC | 3.88% | 3,905,350 | 1.87M | Sep 29, 2024 |
| Blackrock Inc. | 2.37% | 2,391,439 | 1.15M | Sep 29, 2024 |
| 683 Capital Management LLC | 2.12% | 2,138,402 | 1.03M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Horizon Fund-Capital Opportunity Fund | 3.95% | 3,980,425 | 1.91M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.89% | 2,916,871 | 1.40M | Sep 29, 2024 |
| Primecap Odyssey Aggressive Growth Fund | 2.62% | 2,635,691 | 1.27M | Sep 29, 2024 |
| Primecap Odyssey Growth Fund | 1.56% | 1,567,085 | 752.20K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.37% | 1,380,877 | 662.82K | Sep 29, 2024 |
| Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 0.89% | 898,604 | 431.33K | Sep 29, 2024 |